Omeros (NASDAQ:OMER) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.15, Bloomberg Earnings reports. The firm had revenue of $26.80 million during the quarter, compared to the consensus estimate of $25.33 million. The business’s revenue for the quarter was up 1476.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.70) earnings per share.
Shares of NASDAQ:OMER traded up $1.94 during midday trading on Friday, reaching $18.25. 1,308,207 shares of the company were exchanged, compared to its average volume of 405,998. The company’s fifty day moving average is $15.41. Omeros has a one year low of $10.30 and a one year high of $27.00. The firm has a market capitalization of $800.13 million, a PE ratio of -8.22 and a beta of 2.98.
OMER has been the subject of a number of recent analyst reports. Cantor Fitzgerald initiated coverage on shares of Omeros in a research report on Monday, May 6th. They issued an “overweight” rating and a $26.00 price target for the company. Wedbush reiterated a “neutral” rating and issued a $18.00 price target on shares of Omeros in a research report on Monday, July 15th. HC Wainwright set a $35.00 price target on shares of Omeros and gave the stock a “buy” rating in a research report on Tuesday, May 28th. Zacks Investment Research upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, ValuEngine upgraded shares of Omeros from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $25.80.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Story: After-Hours Trading
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.